# Endometrial Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/endometrial-cancer

> 12 upcoming FDA catalysts in endometrial Cancer: sacituzumab tirumotecan (MRK) on Jan to Apr 2028 (topline data readout); sacituzumab tirumotecan (MRK) on January 2028 (primary completion); bnt323/db-1303 (BNTX) on March 2028 (primary completion); bnt323/db-1303 (BNTX) on Mar to Jun 2028 (topline data readout); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 22, 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Endometrial Cancer | completed | "NCT05611931 (Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-22 (ACTUAL); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05611931)) |
| May 29, 2026 | [Pemazyre (pemigatinib) primary completion](https://sec-api.dev/pdufa/pemigatinib) | INCY | Endometrial Cancer | completed | "NCT04463771 (Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-29 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04463771)) |
| Jan to Apr 2028 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Endometrial Cancer | scheduled | "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132958)) |
| January 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Endometrial Cancer | scheduled | "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132958)) |
| March 2028 | [Bnt323/db-1303 primary completion](https://sec-api.dev/pdufa/bnt323-db-1303) | BNTX | Endometrial Cancer | scheduled | "NCT06340568 (A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340568)) |
| Mar to Jun 2028 | [Bnt323/db-1303 topline data readout](https://sec-api.dev/pdufa/bnt323-db-1303) | BNTX | Endometrial Cancer | scheduled | "NCT06340568 (A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06340568)) |
| May 2028 | [Amtagvi® (lifileucel) primary completion](https://sec-api.dev/pdufa/lifileucel) | IOVA | Endometrial Cancer | scheduled | "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06481592)) |
| May to Aug 2028 | [Amtagvi® (lifileucel) topline data readout](https://sec-api.dev/pdufa/lifileucel) | IOVA | Endometrial Cancer | scheduled | "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06481592)) |
| September 2028 | [Sapanisertib primary completion](https://sec-api.dev/pdufa/sapanisertib) | FTH | Endometrial Cancer | scheduled | "NCT06463028 (Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Faeth Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06463028)) |
| Sep to Dec 2028 | [Sapanisertib topline data readout](https://sec-api.dev/pdufa/sapanisertib) | FTH | Endometrial Cancer | scheduled | "NCT06463028 (Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09 (ESTIMATED); Lead Sponsor Faeth Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06463028)) |
| Jan to Apr 2029 | [ENHERTU (trastuzumab deruxtecan) topline data readout](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Endometrial Cancer | scheduled | "NCT06989112 (DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-19 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989112)) |
| January 2029 | [ENHERTU (trastuzumab deruxtecan) primary completion](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) | AZN | Endometrial Cancer | scheduled | "NCT06989112 (DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-19 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989112)) |
| June 2029 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Endometrial Cancer | scheduled | "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06486441)) |
| Jun to Sep 2029 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Endometrial Cancer | scheduled | "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06486441)) |

## Drugs

- [XPOVIO® (selinexor)](https://sec-api.dev/pdufa/selinexor) (KPTI)
- [Pemazyre (pemigatinib)](https://sec-api.dev/pdufa/pemigatinib) (INCY)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303) (BNTX)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [Sapanisertib](https://sec-api.dev/pdufa/sapanisertib) (FTH)
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) (AZN)
- [Sacituzumab govitecan-hziy](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/endometrial-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Endometrial Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/endometrial-cancer

```bibtex
@misc{secapidev_indications_endometrial_cancer_20261116,
  title        = {Endometrial Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/endometrial-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_endometrial_cancer_20261116","title":"Endometrial Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/endometrial-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
